AngioDynamics Beats Q1 Estimates and Announces CEO Succession

Key Facts

1AngioDynamics reported a fiscal Q1 loss of $0.04 per share, narrower than the estimated $0.11 loss.

2Revenue reached $80.90 million, up 6.9% year-over-year, driven by growth in the Med Tech segment.

3The company announced Eric Honroth will succeed Jim Clemmer as CEO effective November 2.

AngioDynamics reported a fiscal Q1 loss of $0.04 per share, which was narrower than the estimated $0.11 loss according to Financial Modeling Prep. Revenue reached $80.90 million, marking a 6.9% increase year-over-year, driven by expansion in the medical technology segment. The company also announced that Eric Honroth will succeed Jim Clemmer as CEO effective November 2, 2026.

ANGO closed at $14.19 on October 7, 2026, with the stock trading between a low of $14.13 and a high of $14.51 during that session. MarketBeat reported that the revenue growth was primarily fueled by a 13.2% rise in Med Tech segment sales, which now accounts for 49% of total revenue. The appointment of Honroth, who previously led Getinge's North American operations, is part of a strategic transition as the company maintains its full-year outlook.